【直击ASCO 2026】亚盛医药耐立克®治疗CML-LBP与Ph+ BCP-ALL数据发布,有望填补急变期治疗空白

美通社
Jun 01

美国马里兰州罗克维尔市和中国苏州2026年6月1日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药(纳斯达克代码:AAPG;香港联交所代码:6855)宣布,公司已在第62届美国临床肿瘤学会(ASCO)年会上,以快速口头报告形式展示了公司核心产品耐立克®(通用名:奥雷巴替尼;研发代号:HQP1351)联合贝林妥欧单抗治疗淋系急变期慢性髓细胞白血病(CML-LBP)或...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10